About EpimAb BiotherapeuticsEpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.
Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule.
CEO: Chengbin Wu, Ph.D
CBO: Dr. Stephan Lensky
Please click here for EpimAb's technology.
19 articles with EpimAb Biotherapeutics
EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer
EpimAb Biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase Ib/II study in patients with non-small cell lung cancer (NSCLC) evaluating the combination of EMB-01, a bispecific antibody designed to simultaneously target EGFR and cMET on tumor cells, and Tagrisso® (osimertinib).
EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X. Zhu
EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Andrew X. Zhu, M.D., Ph.D., to the company’s Scientific Advisory Board.
EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06
EpimAb Biotherapeutics, today announced dose administration for the first patient in a Phase 1/2 clinical trial of EMB-02, a bispecific antibody targeting PD-1 and LAG-3, in patients with advanced solid tumors, as well as in a Phase 1/2 clinical trial of EMB-06, a bispecific antibody targeting B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3), in patients with recurrent and refractory multiple myeloma.
Money on the Move: March 17-23
3/24/2021It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
The life sciences industry is a bustling beehive of activity. Here’s a quick compilation of some of today’s newsworthy announcements.
EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor
IND filing of second bispecific antibody candidate developed from EpimAb’s FIT-Ig® platform
EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Professor Mark Smyth
EpimAb Biotherapeutics announced the appointment of Professor Mark Smyth to the company’s Scientific Advisory Board. Currently a Senior Scientist and the Immunology Department Coordinator at QIMR Berghofer Medical Research Institute, Professor Smyth brings over 20 years of immuno-oncology expertise and research experience to the Scientific Advisory Board.
EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II
EpimAb Biotherapeutics , an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today presented preclinical data at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. The data presented in the poster titled, “ EMB-01: An innovative bispecific antibody targeting EGFR and c
EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations
EpimAb receives exclusive access to newly discovered target combinations in order to expand its proprietary pipeline
EpimAb Biotherapeutics Appoints David Gu, Ph.D. as New Chief Financial Officer to Drive Corporate Development Plans
EpimAb Biotherapeutics announced the appointment of Dr. Xinyi “David” Gu as the new Chief Financial Officer of EpimAb, adding to the current leadership team consisting of Chengbin Wu, Ph.D. CEO; Stephan Lensky, Ph.D. COO and CBO; and Bin Peng, M.D., Ph.D., CMO. Dr. Gu joins EpimAb from Millennium Management where he oversaw investments in global pharmaceutical and biotechnology companies.
EpimAb Biotherapeutics Raises $74M in Series B Financing
Funding to be used in growing and advancing the Company’s clinical pipeline of novel bispecific antibodies
China's EpimAb Biotherapeutics Raises $74 Million in Series B to Advance Solid Tumor Therapy
6/5/2019EpimAb plans to use the funds to advance its Phase I/II clinical program, EMB01, expand its clinical pipeline into immuno-oncology and other areas and add a new manufacturing site in Suzhou for process development and pilot manufacturing.
EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology
Patent protects EpimAb’s core technology FIT-Ig® and its entire bispecific pipeline with a broad composition of matter claim
EpimAb Biotherapeutics Achieves Key Milestone with Lead Cancer Program EMB01
First Patients Dosed with Company’s Novel Bispecific Antibody Format in Phase I/II Clinical Trial
EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US
IND Filing Marks Further Progress Towards the First Clinical Trial with the Company’s Novel Bispecific Antibody Format
EpimAb Biotherapeutics Appoints Industry Veteran Bin Peng as Chief Medical Officer
EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the company as its first Chief Medical Officer.
EpimAb Biotherapeutics Collaborates With Wuxi Biologics To Advance Lead Bispecific Antibody Candidate Towards Clinical Development
EpimAb Biotherapeutics Raises $25M In Series A Financing From International Consortium To Advance Pipeline Of Novel Bispecific Antibodies
Kymab And EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement